Black Rock Inc. Kinnate Biopharma Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Kinnate Biopharma Inc. stock. As of the latest transaction made, Black Rock Inc. holds 431,406 shares of KNTE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

431,406

Previous 586,688 26.47%

Holding current value

Previous $1.39 Million 17.48%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.24 - $2.66 $347,831 - $413,050	-155,282 Reduced 26.47%	431,406 $1.15 Million
Q4 2023 Feb 13, 2024	SELL	$1.07 - $2.5 $165,488 - $386,655	-154,662 Reduced 20.86%	586,688 $1.39 Million
Q3 2023 Nov 13, 2023	BUY	$1.38 - $3.31 $25,320 - $60,731	18,348 Added 2.54%	741,350 $1.04 Million
Q2 2023 Aug 11, 2023	SELL	$2.33 - $6.84 $3.62 Million - $10.6 Million	-1,554,107 Reduced 68.25%	723,002 $2.19 Million
Q1 2023 May 12, 2023	SELL	$3.46 - $7.98 $203,133 - $468,497	-58,709 Reduced 2.51%	2,277,109 $14.2 Million

Q4 2022 Feb 13, 2023	BUY	$5.26 - $12.19 $310,350 - $719,234	59,002 Added 2.59%	2,335,818 $14.2 Million
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $224,098 - $358,193	-22,728 Reduced 0.99%	2,276,816 $27.2 Million
Q2 2022 Aug 12, 2022	BUY	$7.43 - $13.0 $1.82 Million - $3.18 Million	244,320 Added 11.89%	2,299,544 $29 Million
Q1 2022 May 12, 2022	BUY	$7.73 - $17.99 $63,300 - $147,320	8,189 Added 0.4%	2,055,224 $23.1 Million
Q4 2021 Feb 10, 2022	BUY	$16.5 - $25.48 $2.85 Million - $4.4 Million	172,674 Added 9.21%	2,047,035 $36.3 Million
Q3 2021 Nov 09, 2021	BUY	$17.81 - $24.87 $10.7 Million - $14.9 Million	600,832 Added 47.18%	1,874,361 $43.1 Million
Q2 2021 Aug 11, 2021	BUY	$22.19 - $31.55 $28.3 Million - $40.2 Million	1,273,529 New	1,273,529 $29.6 Million

Others Institutions Holding KNTE

# of Institutions

Shares Held

32.9M

Call Options Held

94.7K

Put Options Held

802K

View Full List

About Kinnate Biopharma Inc.

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

More about KNTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account